Skip to main content
. 2020 Mar 13;22(10):1505–1515. doi: 10.1093/neuonc/noaa062

Table 4.

Summary of median OS and PFS times

Covariate Level Median OS Time (mo) Median PFS Time (mo)
Total Failed Censored Median (95% CI) P-value Total Failed Censored Median (95% CI) P-value
All patients 74 60 14 8.11 (6.18, 9.63) 74 70 4 3.71 (2.79, 4.21)
Treatment Bevacizumab 30 23 7 9.26 (5.88, 11.37) 0.6398 30 29 1 3.94 (1.94, 5.68) 0.9401
Bevacizumab  + vorinostat 44 37 7 7.79 (5.06, 9.63) 44 41 3 3.68 (2.33, 3.94)